TY - JOUR
T1 - Deletion of tetraspanin CD151 alters the Wnt oncogene-induced mammary tumorigenesis
T2 - A cell type-linked function and signaling
AU - Li, Hongxia
AU - Li, Jieming
AU - Han, Rongbo
AU - Deng, Xinyu
AU - Shi, Junfong
AU - Huang, Huanhuan
AU - Hamad, Nevean
AU - McCaughley, Abigail
AU - Liu, Jinpeng
AU - Wang, Chi
AU - Chen, Kuey
AU - Wei, Dongping
AU - Qiang, Jun
AU - Thatcher, Sean
AU - Wu, Yadi
AU - Liu, Chunming
AU - Thibault, Olivier
AU - Wei, Xiaowei
AU - Chen, Song
AU - Qian, Hai
AU - Zhou, Binhua P.
AU - Xu, Pao
AU - Yang, Xiuwei H.
N1 - Publisher Copyright:
© 2019 The Authors
PY - 2019/12
Y1 - 2019/12
N2 - Tetraspanin CD151 is increasingly implicated as a multifaceted mediator of cancer development and progression. Here we investigated the role of CD151 in breast cancer in the context of the Wnt oncogenic activation. Our data showed that removal of one or both of CD151 alleles in the MMTV-Wnt1 model significantly decreased the tumor-free survival of mice from 34 weeks on average to 22 weeks and 18 weeks, respectively. This effect coincided with an accelerated tumor growth and an increased number of Ki-67+ proliferative cells. Mechanistically, the CD151-deficient tumors were largely ER+, and exhibited hyperactivation of the Wnt pathway as reflected by a marked upregulation in β-catenin and Cyclin D1, and their target genes. In addition, E-cadherin displayed a cytosolic distribution and transcription factor Snail was markedly upregulated. Collectively, this data implies that CD151 suppresses the Wnt1-driven tumorigenesis, at least in part, via counteracting the epithelial-mesenchymal transition (EMT)-like program in luminal epithelial cells. Meanwhile, the proportion of tumor cells expressing CK5 or p63, the biomarkers of myoepithelial/basal cells, markedly decreased in the absence of CD151. This change was accompanied by a decreased invasiveness of tumors and their incompetence to form a long-term cell culture. Consistent with this basal cell-linked role, the CD151 downregulation impairs mammosphere formation in MCF-10A cells and the defect was rescued by re-expression of intact CD151 ORF, but not its integrin binding-defective mutant. Overall, our study suggests that CD151 is a key player in the Wnt oncogene-driven tumorigenesis and impacts breast cancer malignancy in a cell type-dependent manner.
AB - Tetraspanin CD151 is increasingly implicated as a multifaceted mediator of cancer development and progression. Here we investigated the role of CD151 in breast cancer in the context of the Wnt oncogenic activation. Our data showed that removal of one or both of CD151 alleles in the MMTV-Wnt1 model significantly decreased the tumor-free survival of mice from 34 weeks on average to 22 weeks and 18 weeks, respectively. This effect coincided with an accelerated tumor growth and an increased number of Ki-67+ proliferative cells. Mechanistically, the CD151-deficient tumors were largely ER+, and exhibited hyperactivation of the Wnt pathway as reflected by a marked upregulation in β-catenin and Cyclin D1, and their target genes. In addition, E-cadherin displayed a cytosolic distribution and transcription factor Snail was markedly upregulated. Collectively, this data implies that CD151 suppresses the Wnt1-driven tumorigenesis, at least in part, via counteracting the epithelial-mesenchymal transition (EMT)-like program in luminal epithelial cells. Meanwhile, the proportion of tumor cells expressing CK5 or p63, the biomarkers of myoepithelial/basal cells, markedly decreased in the absence of CD151. This change was accompanied by a decreased invasiveness of tumors and their incompetence to form a long-term cell culture. Consistent with this basal cell-linked role, the CD151 downregulation impairs mammosphere formation in MCF-10A cells and the defect was rescued by re-expression of intact CD151 ORF, but not its integrin binding-defective mutant. Overall, our study suggests that CD151 is a key player in the Wnt oncogene-driven tumorigenesis and impacts breast cancer malignancy in a cell type-dependent manner.
UR - http://www.scopus.com/inward/record.url?scp=85075531145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075531145&partnerID=8YFLogxK
U2 - 10.1016/j.neo.2019.08.005
DO - 10.1016/j.neo.2019.08.005
M3 - Article
C2 - 31783316
AN - SCOPUS:85075531145
SN - 1522-8002
VL - 21
SP - 1151
EP - 1163
JO - Neoplasia (United States)
JF - Neoplasia (United States)
IS - 12
ER -